This elevated TLR4 activation, in turn, contributes to LSEC dysfunction by suppressing eNOS expression, potentially providing a microenvironment conducive to liver fibrosis progression and the exacerbation of portal hypertension. The gene discussed is TLR4; the disease is Hepatic fibrosis.